1800 244 735

Helpline (02) 9874 9777

HDYO! Huntington's Disease Youth Organization goes live

A bright day dawns for young people affected by Huntington’s disease as HDYO, the Huntington’s Disease Youth Organization, is launched. Created for young people, by young people, HDYO represents nothing less than a generation of people affected by HD, standing united to fight the disease together.

Growing up is hard to do

Things can be tough for anyone whose life has been touched by Huntington’s disease. For children, teenagers and young adults, the challenges of growing up in an HD family can be immense, whether it’s seeing loved ones get HD symptoms, caring for unwell family members, coming to terms with being at risk of HD, or even developing juvenile HD themselves.

The problem

Traditional support networks like the Huntington’s disease associations and online communities have done their best to support young people affected by HD, but catering to their particular needs has always been difficult. Recently, powerful social media forces like Twitter and Facebook have enabled young people to become more connected than ever – but good quality, understandable information has been in short supply.

The solution

An inspiring group of young adults from HD families has decided to take action. For the past couple of years, they’ve been planning and developing HDYO, the Huntington’s Disease Youth Organization. HDYO has just launched and its website at hdyo.org is now active. You can also follow HDYO on Twitter (@hdyofeed) and Facebook (hdyouthorg).

A combination of articles, forums, videos and features offers a multitude of information and support. The site is divided into ‘kids’, ‘teens’, ‘young adults’, ‘parents’, ‘professionals’ and ‘JHD’ to make finding appropriate information easy.

It won’t surprise any HDBuzz reader to hear that we are keen on empowering people through good quality information. We think that communication and openness are crucial weapons in the fight against HD. And we can’t think of a better way for the next generation of HD-affected people to take a stand against the disease than to inform, help and support each other.

A responsible team

One understandable concern with a self-support network like HDYO is whether the information and support provided will be dependable. But if HDYO conjures up visions of wild parties and kids running amok, set your mind at ease. The team behind HDYO has assembled a team of expert professionals to advise on their content and make sure that the advice and support given is safe and reliable.

A new day dawns

We couldn’t be more impressed by HDYO. Its founder Matt Ellison, and the other board members, are all HD family members who’ve chosen to fight HD by supporting other young people. We don’t think it’s an exaggeration to see this as a truly inspiring development – a generation of young people, standing together to declare that being affected by HD is nothing to be ashamed of, and offering positive suggestions and solutions for ways to make a real difference, from talking to kids about HD to tips for fundraising and getting involved in research.

It was a similar attitude of optimism and cooperation that led to the discovery of the HD gene in 1993. And we have high hopes that great things will come of HDYO.

The launch of HDYO brings to mind something written by the author Margaret Mead: “Never doubt that a small group of thoughtful, committed people can change the world. Indeed, it is the only thing that ever has.”

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Scientists identify precisely how pridopidine works in models of Huntington’s disease

Published date: 12 June, 2021

Pridopidine is a drug developed to treat Huntington’s disease (HD) and now scientists have a clearer understanding of how it works in the body and brain. In a series of academic papers, researchers figured out that pridopidine is working by targeting a particular receptor protein called S1R. With this new understanding, the researchers believe pridopidine ... Read more

Huntington's disease therapeutics conference 2021 – Day 3

Published date: 29 April, 2021

We are back for the last day of the virtual 2021 CHDI Therapeutics conference. This article summarises our live Twitter updates on the exciting science being presented, which you can find with the hashtag #HDTC2021. The final session of the conference will provide the latest news on more Huntington’s disease clinical programs. A new way ... Read more

Huntington's disease therapeutics conference 2021 – Day 2

Published date: 28 April, 2021

We are back with Day 2 of the virtual 2021 CHDI Therapeutics conference. This article summarises our live Twitter updates on the exciting science being presented, which you can continue to follow with the hashtag #HDTC2021. The morning session focussed on promising HD therapeutics that are in preclinical development and the afternoon session covered different ... Read more

Huntington’s disease therapeutics conference 2021 – Day 1

Published date: 28 April, 2021

The CHDI Therapeutics Conference 2021 kicked off today. This article summarizes our live Twitter updates on the exciting science being presented, which you can continue to follow with the hashtag #HDTC2021. The morning of Day 1 focused on clinical trial updates, while the afternoon explored genetic modifiers of HD and how they might be harnessed ... Read more

Huntington’s disease clinical trial round up

Published date: 26 April, 2021

It seems like the HD community has been inundated with updates from different companies and clinical trials recently. The news is far from complete doom and gloom; although there have been some real disappointments from some of the frontrunner trials, there are also positive updates from many different companies and lots of reasons for us ... Read more

Good news from uniQure: gene therapy trial on track, and promising data in animals

Published date: 15 April, 2021

Two recent press releases from uniQure provide welcome good news: the first ever HD gene therapy, known as AMT-130, has been administered via brain surgery to a small set of participants in an early safety trial. At the same time, uniQure has published findings in HD animal models that increase confidence in the drug’s ability ... Read more